Novavax

YTD

ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines.

CEO

John C.s Jacobs

CEOJohn C.s Jacobs

Employees

952

Employees952

Headquarters

Gaithersburg, Maryland

HeadquartersGaithersburg, Maryland

Founded

1987

Founded1987

Employees

952

Employees952

NVAX Key Statistics

Market cap

1.54B

Market cap1.54B

Price-Earnings ratio

4.19

Price-Earnings ratio4.19

Dividend yield

—

Dividend yield—

Average volume

4.29M

Average volume4.29M

High today

$9.75

High today$9.75

Low today

$9.24

Low today$9.24

Open price

$9.59

Open price$9.59

Volume

5.01M

Volume5.01M

52 Week high

$14.70

52 Week high$14.70

52 Week low

$5.01

52 Week low$5.01

NVAX News

Simply Wall St 37m

What Do Recent Novavax Gains Mean After the Sanofi Partnership Announcement?

If you have been eyeing Novavax lately, you are definitely not alone. Investors are talking about this vaccine maker again, especially after the stock posted an...

Simply Wall St 1d

Novavax Is Up 14.5% After Sanofi Expands Use of Matrix-M Adjuvant Technology - What's Changed

Sanofi recently announced an expanded agreement with Novavax, granting broader rights to use Novavax’s Matrix-M adjuvant in the early-stage development of its p...

Nasdaq 4d

Novavax Expands Collaboration And License Agreement With Sanofi On Use Of Matrix-M Adjuvant

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M a...

Analyst ratings

50%

of 8 ratings

Buy

50%

Hold

12.5%

Sell

37.5%

More NVAX News

TipRanks 4d

Novavax announces progress on Sanofi agreement

Novavax (NVAX) announced progress on its collaboration and license agreement with Sanofi (SNY) regarding Novavax’s Matrix-M adjuvant. The companies have amended...

Simply Wall St 6d

Novavax: Exploring Valuation After Analyst Upgrades and Renewed Investor Interest

Advertisement Most Popular Narrative: 31.6% Undervalued Novavax (NVAX) is catching the attention of many investors lately, and it is not just because of anoth...

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.